The University of Southampton
University of Southampton Institutional Repository

A phase II trial of marimastat in advanced pancreatic cancer

Evans, J.D., Stark, A., Johnson, C.D., Daniel, F., Carmichael, J., Buckels, J., Imrie, C.W., Brown, P. and Neoptolemos, J.P. (2001) A phase II trial of marimastat in advanced pancreatic cancer British Journal of Cancer, 85, (12), pp. 1865-1870.

Record type: Article


Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted.

Full text not available from this repository.

More information

Published date: 2001
Keywords: pancreatic cancer, matrix metalloproteinases, marimastat, toxicity


Local EPrints ID: 26300
ISSN: 0007-0920
PURE UUID: dde9f2d2-10a2-4567-9b75-c726793c5b28

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 17 Jul 2017 16:07

Export record


Author: J.D. Evans
Author: A. Stark
Author: C.D. Johnson
Author: F. Daniel
Author: J. Carmichael
Author: J. Buckels
Author: C.W. Imrie
Author: P. Brown
Author: J.P. Neoptolemos

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.